Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.

Tamoxifen use in breast cancer not linked to acute pancreatitis

2 months ago
There are studies ongoing to grow human organs in pigs to help address lack of organs for transplants.

The use of tamoxifen in breast cancer patients is not associated with the incidence of acute pancreatitis (AP), a new study shows.

The population-based cohort study used data from the National Health Insurance Research Database of Taiwan. New-onset breast cancer patients at least 20 years of age were included. Those with histories of pancreatic cancer and acute and chronic pancreatitis were excluded.

The accumulated defined daily dose (DDD) of tamoxifen prescribed during the follow-up periodwas calculated. Prescription information was calculated yearly after the index date to account for changes in drug use over time.

Before propensity score matching, 22,005 patients (mean age53.4 years)did not receive tamoxifen while 40,484 did (mean age 51.4 years). Asthma (p=0.01) and hyperlipidaemia (p<0.001) were more common in nonusers while fluorouracil use was more common in tamoxifen users (p<0.001). Differences disappeared after propensity score matching.

Alcohol-related diseases (adjusted hazard ratio [aHR], 1.56; 95 percent CI, 0.50 to 4.88), despite being known to cause chronic and acute pancreatitis, were not associated with AP after controlling for age. Similarly, hepatitis B (aHR, 1.15; 0.62 to 2.10) and hepatitis C (aHR, 1.28; 0.63 to 2.61) virus infections were also not associated with AP.

On the other hand, diabetes mellitus (aHR, 1.63; 1.23 to 2.61) and gallstones (aHR, 3.19; 2.33 to 4.35) correlated with an increased risk of AP after controlling for age.

After adjustment for age, comorbidities and medications, the risk of AP was not significant between tamoxifen users and nonusers (aHR, 0.94; 0.74 to 1.19) in the nonmatching cohorts. No dose–response trend existed between tamoxifen use and the risk of AP (aHR, 0.98; 0.96 to 1.00).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Catherine J Calderwood, MA (Cantab), MRCOG; Omar I Thanoon, MRCOG, 3 years ago

One of the many early physiological adaptations of pregnancy involves changes in the coagulation system, which promote coagulation and impair fibrinolysis. The physiological goal is to prepare for the haemostatic challenge of delivery. A ‘side effect’ of this change is an increased risk of thrombosis. All pregnant women are therefore at risk of thrombosis, compared with non-pregnant women. This risk is manifest from early in the first trimester until 4−6 weeks post partum.

one year ago
Routine laboratory factors predict adverse pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy, according to a prospective, case control study.